A complete list of the participants in this research study appears at the end of this article.
Twenty-Four-Hour Effectiveness of BMS 180048 in the Acute Treatment of Migraine Headaches
Article first published online: 19 JAN 2002
Headache: The Journal of Head and Face Pain
Volume 37, Issue 4, pages 245–248, April, 1997
How to Cite
Ryan, R.E., Elkind, A. and Goldstein, J. (1997), Twenty-Four-Hour Effectiveness of BMS 180048 in the Acute Treatment of Migraine Headaches. Headache: The Journal of Head and Face Pain, 37: 245–248. doi: 10.1046/j.1526-4610.1997.3704245.x
Presented at the 38th Annual Scientific Meeting of the American Association for the Study of Headache, San Diego, Calif, May 31, 1996.
- Issue published online: 19 JAN 2002
- Article first published online: 19 JAN 2002
- Accepted for publication October 30, 1996.
- Cited By
- migraine headache;
- BMS 180048;
- abortive therapy
The efficacy of BMS 180048, a 5HT, agonist in the acute treatment of a migraine headache, was evaluated in 216 patients. Three doses of the study drug were compared to placebo. Patients received a single test dose in the physician’s office while being evaluated with a Holter monitor during a headache-free day. They then treated a migraine headache with a single dose of the study drug as an outpatient. The 150 mg and 200mg doses of BMS were significantly superior to placebo on change in pain intensity at 2 hours. Patients treated with BMS 180048 had a longer duration of response than placebo-treated patients. At the 24hour point, only 24% of the 150mg group and 25% of the 200mg group had relapsed, compared to placebo which had a 42% relapse rate. It is concluded that BMS 180048 is an effective compound for the treatment of migraine headaches with a prolonged duration of response.